Mirati Therapeutics & SCRI announce strategic, community site focused partnership
“The opportunity to partner with SCRI enables Mirati to advance diversity in our clinical studies, which is a key pillar of our Diversity, Equity, and Inclusion efforts. We are excited about the opportunity to leverage the expertise and scale of SCRI as we collaborate on a range of initiatives aimed at improving health outcomes for a broad range of patients.” said Alan Sandler, M.D., chief medical officer, Mirati Therapeutics, Inc. “By focusing on community-based sites, we can better understand the health needs of patients living with cancer and provide more tailored, patient-centered care. This partnership will allow us to gain a deeper understanding of the challenges patients face to enable us to better design our clinical studies to be representative of all patient communities.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us